Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
First Claim
Patent Images
1. A compound of the following formula, or a salt thereof:
-
wherein the symbols have the following meanings and are, for each occurrence, independently selected;
G is an aryl or heteroaryl group, where said group is mono- or polycyclic and is optionally substituted at one or more positions;
A1 is CR7;
A2 is CR7;
Y is O, S, or (CR7R7′
)n wherein n=1 or 2;
W is CR7R7′
—
CR7R7′
or CR8═
CR8′
;
Q1 is H, alkyl or substituted alkyl;
Q2 is H, alkyl or substituted alkyl;
R1 and R1′
are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, and/or arylalkyl or substituted arylalkyl;
R2 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl;
R4 is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, R1C═
O, R1NHC═
O, R1OC═
O;
SO2OR1, or SO2NR1R1′
;
R5 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, R1C═
O, R1NHC═
O, SO2R1, SO2OR1, or SO2NR1R1′
;
R7 and R7′
are at each occurrence independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, halo, N3, CN, OR1, O(C═
O)R1, O(C═
O)NHR1, O(C═
O)OR1, nitro, hydroxylamine, hydroxylamide, amino, SR1, SeR1, NHR4, NR2R5, NOR1, thiol, alkylthio or substituted alkylthio, R1C═
O, R1OC═
O, R1NHC═
O, SO2R1, SOR1, PO3R1R1′
, R1R1′
NC═
O, C═
OSR1, SO2R1, SO2OR1, SO2NR1R1′
, OSO2-aryl, OSO2-(substituted aryl), OSO2-heterocyclo, OSO2-(substituted heterocyclo), and/or COCl;
R8 and R8′
are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, nitro, halo, CN, OR1, amino, NHR4, NR2R5, NOR1, alkylthio or substituted alkylthio, C═
OSR1, R1OC═
O, R1C═
O, R1NHC═
O, R1R1′
NC═
O, SO2OR1, S═
OR1, SO2R1, PO3R1R1′
, and/or SO2NR1R1′
;
with the proviso that when A1 and A2 are CH;
Y is O or CH2;
W is CH2—
CH2 or CH═
CH;
Q2 is H or CH2OH; and
Q2 is H or CH2OH, then (i) G is not pyridinyl, phenyl, dichlorophenyl, bromophenyl or methoxyphenyl when R7a or R7a′
is OH or OCH3 and (ii) G is not methoxyphenyl or phenyl substituted with —
OCH2CH2-SB where SB is dimethylamino, diethylamino, piperidinyl, morpholinyl, or pyrrolidinyl when R7a and R7a′
are both hydrogen.
1 Assignment
0 Petitions
Accused Products
Abstract
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
16 Citations
25 Claims
-
1. A compound of the following formula, or a salt thereof:
-
wherein the symbols have the following meanings and are, for each occurrence, independently selected; G is an aryl or heteroaryl group, where said group is mono- or polycyclic and is optionally substituted at one or more positions;
A1 is CR7;
A2 is CR7;
Y is O, S, or (CR7R7′
)n wherein n=1 or 2;
W is CR7R7′
—
CR7R7′
or CR8═
CR8′
;
Q1 is H, alkyl or substituted alkyl;
Q2 is H, alkyl or substituted alkyl;
R1 and R1′
are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, and/or arylalkyl or substituted arylalkyl;
R2 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl;
R4 is H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, R1C═
O, R1NHC═
O, R1OC═
O;
SO2OR1, or SO2NR1R1′
;
R5 is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, R1C═
O, R1NHC═
O, SO2R1, SO2OR1, or SO2NR1R1′
;
R7 and R7′
are at each occurrence independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, halo, N3, CN, OR1, O(C═
O)R1, O(C═
O)NHR1, O(C═
O)OR1, nitro, hydroxylamine, hydroxylamide, amino, SR1, SeR1, NHR4, NR2R5, NOR1, thiol, alkylthio or substituted alkylthio, R1C═
O, R1OC═
O, R1NHC═
O, SO2R1, SOR1, PO3R1R1′
, R1R1′
NC═
O, C═
OSR1, SO2R1, SO2OR1, SO2NR1R1′
, OSO2-aryl, OSO2-(substituted aryl), OSO2-heterocyclo, OSO2-(substituted heterocyclo), and/or COCl;
R8 and R8′
are each independently selected from H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, nitro, halo, CN, OR1, amino, NHR4, NR2R5, NOR1, alkylthio or substituted alkylthio, C═
OSR1, R1OC═
O, R1C═
O, R1NHC═
O, R1R1′
NC═
O, SO2OR1, S═
OR1, SO2R1, PO3R1R1′
, and/or SO2NR1R1′
;
with the proviso that when A1 and A2 are CH;
Y is O or CH2;
W is CH2—
CH2 or CH═
CH;
Q2 is H or CH2OH; and
Q2 is H or CH2OH, then (i) G is not pyridinyl, phenyl, dichlorophenyl, bromophenyl or methoxyphenyl when R7a or R7a′
is OH or OCH3 and (ii) G is not methoxyphenyl or phenyl substituted with —
OCH2CH2-SB where SB is dimethylamino, diethylamino, piperidinyl, morpholinyl, or pyrrolidinyl when R7a and R7a′
are both hydrogen.- View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
wherein G, Y, W, Q1, Q2, R7, and R7′
are as defined in claim 1, andR20 is where the R7a groups are independently selected from those groups included in the definition of R7, comprising the step of contacting a compound of the following formula X;
with a Lewis acid and a compound of the formula (R1)3SiR20.
-
-
4. A compound according to claim 1, or a pharmaceutically-acceptable salt thereof, wherein at least one of A1 and A2 is —
- C(CH3).
-
5. A compound according to claim 1, or a pharmaceutically-acceptable salt thereof, wherein G is phenyl or napthyl and said group G substituted with one, two or three substituents selected from trifluoromethyl, halogen, cyano, nitro, and/or lower alkyl.
-
6. A compound according to claim 1, or a pharmaceutically-acceptable salt thereof, wherein G is a group,
wherein X is trifluoromethyl or cyano and X′ - is trifluoromethyl, halogen, cyano, nitro, or lower alkyl.
-
7. A compound according to claim 1, or a pharmaceutically-acceptable salt thereof, wherein Y is O.
-
8. A compound according to claim 1, or a pharmaceutically-acceptable salt thereof, wherein R7, and R7′
- , R7a and R7a′
are each independently selected from H, alkyl, OH, O(alkyl), alkenyl, cyano, O(C═
O)R1, O(C═
O)NHR1, O(C═
O)OR1, nitro, amino, SR1, NHR4, alkylthio, R1C═
O, R1OC═
O, R1NHC═
O, SO2R1, SOR1, SO2NR1R1′
, OSO2-aryl, OSO2-(substituted aryl), OSO2-heterocyclo, OSO2-(substituted heterocyclo), and/or COCl.
- , R7a and R7a′
-
9. A compound according to claim 1, having the formula,
wherein R7, R7′ - , R7a, and R8 are at each occurrence independently selected from H, alkyl, OH, O(alkyl), alkenyl, cyano, O(C═
O)R1, nitro, amino, SR1, NHR4, alkylthio, R1C═
O, R1OC═
O, R1NHC═
O, SO2R1, SOR1, SO2NR1R1′
, OSO2-aryl, OSO2-(substituted aryl), OSO2-heterocyclo, OSO2-(substituted heterocyclo), and/or COCl;
or a pharmaceutically-acceptable salt thereof.
- , R7a, and R8 are at each occurrence independently selected from H, alkyl, OH, O(alkyl), alkenyl, cyano, O(C═
-
10. A compound according to claim 9, or a pharmaceutically-acceptable salt thereof, wherein at least one of A1 and A2 is —
- C(alkyl).
-
11. A compound according to claim 9, or a pharmaceutically-acceptable salt thereof, wherein A1 and A2 are both —
- C(CH3).
-
12. A compound according to claim 9, or a pharmaceutically-acceptable salt thereof, wherein G is phenyl or napthyl and said group G is substituted with one, two or three substituents selected from trifluoromethyl, halogen, cyano, nitro, and/or lower alkyl.
-
13. A compound according to claim 9, or a pharmaceutically-acceptable salt thereof, wherein G is a group,
wherein X is trifluoromethyl or cyano and X′ - is trifluoromethyl, halogen, cyano, nitro, or lower alkyl.
-
14. A compound according to claim 1, having the formula,
wherein R7, R7′ - , R7a, and R8 are at each occurrence independently selected from H, alkyl, OH, O(alkyl), alkenyl, cyano, O(C═
O)R1, nitro, amino, SR1, NHR1, alkylthio, R1C═
O, R1OC═
O, R1NHC═
O, SO2R1, SOR1, SO2NR1R1′
, OSO2-aryl, OSO2-(substituted aryl), OSO2-heterocyclo, OSO2-(substituted heterocyclo), and/or COCl;
or a pharmaceutically-acceptable salt.
- , R7a, and R8 are at each occurrence independently selected from H, alkyl, OH, O(alkyl), alkenyl, cyano, O(C═
-
15. A compound according to claim 14, or a pharmaceutically-acceptable salt thereof, wherein at least one of A1 and A2 is —
- C(alkyl).
-
16. A compound according to claim 14, or a pharmaceutically-acceptable salt thereof, wherein A1 and A2 are both —
- C(CH3).
-
17. A compound according to claim 14, or a pharmaceutically-acceptable salt thereof, wherein G is phenyl or napthyl and said group G is substituted with one, two or three substituents selected from trifluoromethyl, halogen, cyano, nitro, and/or lower alkyl.
-
18. A compound according to claim 14, or a pharmaceutically-acceptable salt thereof, wherein G is a group,
wherein X is trifluoromethyl or cyano and X′ - is trifluoromethyl, halogen, cyano, nitro, or lower alkyl.
-
2. A compound of selected from the group consisting of (i):
-
(3aα
,4α
,7α
,7aα
)-Octahydro-3-hydroxy-2-[4-nitro-3-(trifluoromethyl)phenyl]-4,7-methano-1H-isoindol-1-one (2);
(3aα
,4α
,7α
,7aα
)-Octahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-4,7-methano-1H-isoindol-1-one (3);
(3aα
,4α
,7α
,7aα
)-2,3,3a,4,7,7a-Hexahydro-3-hydroxy-2-[4-nitro-3-(trifluoromethyl)phenyl]-4,7-methano-1H-isoindol-1-one (4);
(3aα
,4α
,7α
,7aα
)-2-[4-Bromo-3-(trifluoromethyl)phenyl]-2,3,3a,4,7,7a-hexahydro-3-methoxy-4,7-methano-1H-isoindol-1-one (5);
(3aα
,4α
,7α
,7aα
)-Octahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-3-(2-propenyl)-4,7-methano-1H-isoindol-1-one (6);
(3aα
,4β
,7β
,7aα
)-Octahydro-3-hydroxy-2-(4-nitro-1-naphthalenyl)-4,7-epoxy-1H-isoindol-1-one (7);
(3aα
,4β
,7β
,7aα
)-Octahydro-2-(4-nitro-1-naphthalenyl)-4,7-epoxy-1H-isoindol-1-one (8);
(3aα
,4α
,7α
,7aα
)-2,3,3a,4,7,7a-Hexahydro-3-hydroxy-2-[3-(trifluoromethyl)phenyl]-4,7-ethano-1H-isoindol-1-one (9);
(3aα
,4α
,7α
,7aα
)-2,3,3a,4,7,7a-Hexahydro-2-[3-(trifluoromethyl)phenyl]-4,7-ethano-1H-isoindol-1-one (10);
(1α
,3aα
,4α
,7α
,7aα
)-2,3,3a,4,7,7a-Hexahydro-2-(4-nitro-1-naphthalenyl)-3-oxo-4,7-methano-1H-isoindole-1-carbonitrile (12B);
(3aα
,4β
,7β
,7aα
)-2,3,3a,4,7,7a-Hexahydro-3-hydroxy-4,7-dimethyl-2-[3-(trifluoromethyl)phenyl]-4,7-epoxy-1H-isoindol-1-one (13B);
(3aα
,4β
,7β
,7aα
)-Octahydro-3-hydroxy-4,7-dimethyl-2-[3-(trifluoromethyl)phenyl]-4,7-epoxy-1H-isoindol-1-one (14);
(3aα
,4α
,7α
,7aα
)-2-(1,2-Dihydro-4-methyl-2-oxo-7-quinolinyl)-2,3,3a,4,7,7a-hexahydro-3-methoxy-4,7-methano-1H-isoindol-1-one;
(3aα
,4α
,7α
,7aα
)-Octahydro-3-methoxy-2-(1-naphthalenyl)-4,7-methano-1H-isoindol-1-one;
(3aα
,4α
,7α
,7aα
)-2-[4-Bromo-3-(trifluoromethyl)phenyl]-2,3,3a,4,7,7a-hexahydro-4,7-methano-1H-isoindol-1-one;
(3aα
,4α
,7α
,7aα
)-Octahydro-2-(1-naphthalenyl)-4,7-methano-1H-isoindol-1-one;
(3aα
,4α
,7α
,7aα
)-2-(1,2-Dihydro-4-methyl-2-oxo-7-quinolinyl)-2,3,3a,4,7,7a-hexahydro-4,7-methano-1H-isoindol-1-one;
(3aα
,4α
,7α
,7aα
)-2-(3,5-Dichlorophenyl)-2,3,3a,4,7,7a-hexahydro-4,7-methano-1H-isoindol-1-one;
(3aα
,4α
,7α
,7aα
)-2-(4-Bromo-1-naphthalenyl)-2,3,3a,4,7,7a-hexahydro-4,7-methano-1H-isoindol-1-one;
(3aα
,4α
,7α
,7aα
)-2-[4-Bromo-3-(trifluoromethyl)phenyl]-2,3,3a,4,7,7a-hexahydro-3-hydroxy-4,7-methano-1H-isoindol-1-one;
(3aα
,4α
,7α
,7aα
)-2,3,3a,4,7,7a-Hexahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-4,7-methano-1H-isoindol-1-one;
(3aα
,4α
,7α
,7aα
)-2-[4-Bromo-3-(trifluoromethyl)phenyl]-2,3,3a,4,7,7a-hexahydro-3-hydroxy-5-methyl-4,7-methano-1H-isoindol-1-one;
(1α
,3aα
,4α
,7α
,7aα
)-2,3,3a,4,7,7a-Hexahydro-2-[4-nitro-3-(trifluoromethyl)phenyl]-3-oxo-4,7-methano-1H-isoindole-1-carbonitrile; and
(3aα
,4α
,7α
,7aα
)-2,3,3a,4,7,7a-Hexahydro-2-(4-nitro-1-naphthalenyl)-4,7-methano-1H-isoindol-1-one; and
(ii) a pharmaceutically acceptable salt.
-
-
19. A compound having the formula,
wherein, Y is — - O—
, —
S—
, —
CR7′
R7′
—
, or —
(CR7′
R7′
)2—
;
W is —
CR7R7′
—
CR7R7′
—
or —
CR8═
CR8′
—
;
R7 and R8 are each independently H, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, cycloalkenylalkyl or substituted cycloalkenylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, halo, N3, CN, OR1, O(C═
O)R1, O(C═
O)NHR1, O(C═
O)OR1, nitro, hydroxylamine, hydroxylamide, amino, SR1, NR4R5, alkylthio or substituted alkylthio, R1C═
O, R1OC═
O, R1NHC═
O, SO2R1, SOR1, SO2NR1R1′
, OSO2-aryl, OSO2-(substituted aryl), OSO2-heterocyclo, OSO2-(substituted heterocyclo), or COCl;
R7′
and R8′
are at each occurrence independently selected from H, alkyl, substituted alkyl, OH, O(alkyl), alkenyl, and/or cyano;
R1 and R1′
are independently selected from H, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkyalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, and arylalkyl or substituted arylalkyl;
R4 and R5 are independently selected from H, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocyclo or substituted heterocyclo, cycloalkylalkyl or substituted cycloalkylalkyl, heterocycloalkyl or substituted heterocycloalkyl, aryl or substituted aryl, arylalkyl or substituted arylalkyl, R1C═
O, R1NHC═
O, R1OC═
O;
SO2OR1, and SO2NR1R1′
;
X is selected from trifluoromethyl, halogen, cyano, nitro, and/or alkyl; and
y is 0, 1, 2, or 3;
or a pharmaceutically-acceptable salt. - View Dependent Claims (20, 22, 23, 24, 25)
- O—
-
21. A compound having the formula,
or a pharmaceutically-acceptable salt thereof.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeBristol-Myers Squibb Company
-
Original AssigneeBristol-Myers Squibb Company
-
InventorsZhu, Hong, Salvati, Mark E., Balog, James Aaron, Pickering, Dacia A.
-
Primary Examiner(s)SAEED, KAMAL A
-
Application NumberUS10/322,276Publication NumberTime in Patent Office1,329 DaysField of Search548/453US Class Current514/412CPC Class CodesA61P 13/08 of the prostateA61P 15/00 Drugs for genital or sexual...A61P 15/12 for climacteric disordersA61P 15/18 Feminine contraceptivesA61P 17/00 Drugs for dermatological di...A61P 17/14 for baldness or alopeciaA61P 19/10 for osteoporosisA61P 25/18 Antipsychotics, i.e. neurol...A61P 25/28 for treating neurodegenerat...A61P 25/36 Opioid-abuseA61P 3/06 AntihyperlipidemicsA61P 3/10 for hyperglycaemia, e.g. an...A61P 35/00 Antineoplastic agentsA61P 37/00 Drugs for immunological or ...A61P 43/00 Drugs for specific purposes...A61P 5/26 AndrogensA61P 9/00 Drugs for disorders of the ...A61P 9/02 Non-specific cardiovascular...C07D 209/74 with an oxygen atom in posi...C07D 209/76 with oxygen atoms in positi...View All
